Cancer Drug Encyclopedia
Approved oncology medications — what they treat, how they work and key safety information.
Relapsed or refractory B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Mantle Cell Lymphoma, or Multiple Myeloma.
Relapsed or refractory B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Mantle Cell Lymphoma, or Multiple Myeloma.
Locally advanced or metastatic urothelial carcinoma, non-small cell lung cancer, extensive-stage small cell lung cancer (ES-SCLC), and unresectable hepatocellular carcinoma in combination with bevacizumab.
Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Urothelial Cancer, Head and Neck Cancer, MSI-H/dMMR solid tumors, and Cervical Cancer.
Relapsed/refractory Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Small Cell Lung Cancer, or Acute Lymphoblastic Leukemia.
Relapsed/refractory Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Small Cell Lung Cancer, or Acute Lymphoblastic Leukemia.
Brain Tumors (Glioblastoma, Astrocytoma), Multiple Myeloma, Lymphomas, Leukemias, Sarcomas, and conditioning regimens.
Brain Tumors (Glioblastoma, Astrocytoma), Multiple Myeloma, Lymphomas, Leukemias, Sarcomas, and conditioning regimens.
Approved for use in oncology care according to FDA-approved indications.
Approved for use in oncology care according to FDA-approved indications.
Advanced solid tumors and hematologic malignancies with matching genomic alterations.
Advanced solid tumors and hematologic malignancies with matching genomic alterations.